運輸方式： 凍存運輸

細胞形態(tài)： **樣

**類型： IgG1; kappa light chain

數(shù)量： 大量

ATCC Number： HB-11534?

生長狀態(tài)： 懸浮生長

是否是腫瘤細胞： 0

物種來源： 大鼠

Designations: DC101

Depositors: ImClone Systems Inc.

Isotype: IgG1; kappa light chain

Biosafety Level: 1

Shipped: frozen

DC101細胞Medium & Serum: See Propagation

Growth Properties: suspension

Organism: Rattus norvegicus (B cell); Mus musculus (myeloma) deposited as rat (B cell); mouse (myeloma)

Morphology: lymphoblast

Source: Cell Type: hybridoma:

Cellular Products: immunoglobulin; monoclonal antibody; against murine vascular endothelial growth factor (VEGF) receptor-2 (Flk-1/KDR)

Permits/Forms: In addition to the MTA mentioned above, other ATCC and/or regulatory permits may be required for the transfer of this ATCC material. Anyone purchasing ATCC material is ultimately responsible for obtaining the permits. Please click here for information regarding the specific requirements for shipment to your location.

Applications: DC101 was found to be specific for the murine tyrosine kinase receptor FLK-1. ELISA data showed that the antibody bound to purified FLK-1:SEAP but not alkaline phosphatase or other receptor tyrosine kinases such as FLK-2.

Treatment with DC101 antibody completely inhibits the growth of established epidermoid, glioblastoma, pancreatic, and renal human tumor xenografts by suppression of tumor-induced neovascularization

Comments: DC101 was found to be specific for the murine tyrosine kinase receptor FLK-1.DC101細胞 ELISA data showed that the antibody bound to purified FLK-1:SEAP but not alkaline phosphatase or other receptor tyrosine kinases such as FLK-2.

DC101 does not cross-react with the human VEGFR2/KDR.

Treatment with DC101 antibody completely inhibits the growth of established epidermoid, glioblastoma, pancreatic, and renal human tumor xenografts by suppression of tumor-induced neovascularization

Animals were hyperimmunized with an immune complex consisting of the mouse FLK-1:SEAPs soluble receptor, a rabbit anti-alkaline phosphatase polyclonal antibody and Protein-G sepharose beads.

Spleen cells were fused with NS-1 mouse myeloma cells.

Propagation: ATCC complete growth medium: The base medium for this cell line is ATCC-formulated Dulbecco's Modified Eagle's Medium, Catalog No. 30-2002. To make the complete growth medium, add the following components to the base medium: fetal bovine serum to a final concentration of 10%.

Temperature: 37.0°C

Subculturing: Protocol: Cultures can be maintained by the addition of fresh medium or replacement of medium. Alternatively, cultures can be established by centrifugation with subsequent resuspension at 2 X 10 exp5 viable cells/ml. Maintain cell density between 1 X 10 exp5 and 1 X 10 exp6 viable cells/ml.

Medium Renewal: Every 2 to 3 days

Preservation: Freeze medium: Complete growth medium 92.5%; DMSO, 7.5%

Storage temperature:DC101細胞 liquid nitrogen vapor phase

Related Products: Recommended medium (without the additional supplements or serum described under ATCC Medium):ATCC 30-2002

recommended serum:ATCC 30-2020

References: 47436: Rockwell P, Goldstein NI. Monoclonal antibodies specific to VEGF receptors and uses thereof. US Patent 5,955,311 dated Sep 21 1999

55760: Witte L, et al. Monoclonal antibodies targeting the VEGF receptor-2 (Flk1/KDR) as an anti-angiogenic therapeutic strategy. Cancer Metastasis Rev. 17: 155-161, 1998. PubMed: 9770111

56114: Prewett M, et al. Antivascular endothelial growth factor receptor (fetal liver kinase 1) monoclonal antibody inhibits tumor angiogenesis and growth of several mouse and human tumors. Cancer Res. 59: 5209-5218, 1999. PubMed: 10537299

56115: Shaheen RM, et al. Effects of an antibody to vascular endothelial growth factor receptor-2 on survival, tumor vascularity, and apoptosis in a murine model of colon carcinomatosis. Int. J. Oncol. 18: 221-226, 2001. PubMed: 11172585

56116: Kadambi A, et al. DC101細胞Vascular endothelial growth factor (VEGF)-C differentially affects tumor vascular function and leukocyte recruitment: role of VEGF-receptor 2 and host VEGF-A. Cancer Res. 61: 2404-2408, 2001. PubMed: 11289105

56117: Kozin SV, et al. Vascular endothelial growth factor receptor-2-blocking antibody potentiates radiation-induced long-term control of human tumor xenografts. Cancer Res. 61: 39-44, 2001. PubMed: 11196192

56142: Zimmermann RC, et al. Preovulatory treatment of mice with anti-VEGF receptor 2 antibody inhibits angiogenesis in corpora lutea. Microvasc. Res. 62: 15-25, 2001. PubMed: 11421657

56143: Klement G, et al. Continuous low-dose therapy with vinblastine and VEGF receptor-2 antibody induces sustained tumor regression without overt toxicity. J. Clin. Invest. 105: R15-R24, 2000. PubMed: 10772661

56145: Stoelcker B, et al. VEGF/Flk-1 interaction, a requirement for malignant ascites recurrence. J. Inferon Cytokine Res. 20: 511-517, 2000. PubMed: 10841080